These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 30416696

  • 1. Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.
    Yassin MA, Soliman AT, De Sanctis V, Hussein RM, Al-Okka R, Kassem N, Ghasoub R, Basha A, Nashwan AJ, Adel AM.
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018064. PubMed ID: 30416696
    [Abstract] [Full Text] [Related]

  • 2. Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.
    Kanbour I, Chandra P, Soliman A, De Sanctis V, Nashwan A, Abusamaan S, Moustafa A, Yassin MA.
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018062. PubMed ID: 30416694
    [Abstract] [Full Text] [Related]

  • 3. Iron Overload in Patients With Heavily Transfused Sickle Cell Disease-Correlation of Serum Ferritin With Cardiac T2* MRI (CMRTools), Liver T2* MRI, and R2-MRI (Ferriscan®).
    Alkindi S, Panjwani V, Al-Rahbi S, Al-Saidi K, Pathare AV.
    Front Med (Lausanne); 2021; 8():731102. PubMed ID: 34760898
    [Abstract] [Full Text] [Related]

  • 4. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD).
    Yassin MA, Soliman AT, De Sanctis V, Abdula MAJ, Riaz LM, Ghori FF, Yousaf A, Nashwan AJ, Abusamaan S, Moustafa A, Kohla S, Soliman DS.
    Acta Biomed; 2018 Feb 16; 89(2-S):33-40. PubMed ID: 29451227
    [Abstract] [Full Text] [Related]

  • 5. Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy.
    Soliman A, Yassin M, Al Yafei F, Al-Naimi L, Almarri N, Sabt A, De Sanctis V.
    Mediterr J Hematol Infect Dis; 2014 Feb 16; 6(1):e2014025. PubMed ID: 24803998
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.
    Ann Hematol; 2013 Jan 16; 92(2):211-9. PubMed ID: 23086508
    [Abstract] [Full Text] [Related]

  • 8. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 9. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT, Yassin MA, De Sanctis V.
    Acta Biomed; 2018 Feb 16; 89(2-S):27-32. PubMed ID: 29451226
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Feb 16; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A.
    Eur J Haematol; 2009 Jun 16; 82(6):458-65. PubMed ID: 19187278
    [Abstract] [Full Text] [Related]

  • 12. Liver Iron Content (LIC) in Adults with Sickle Cell Disease (SCD): Correlation with Serum Ferritin and Liver Enzymes Concentrations in Trasfusion Dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD) Patients.
    Yassin M, Soliman A, De Sanctis V, Nashwan A, Abusamaan S, Moustafa A, Kohla S, Soliman D.
    Mediterr J Hematol Infect Dis; 2017 Jun 16; 9(1):e2017037. PubMed ID: 28698780
    [Abstract] [Full Text] [Related]

  • 13. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
    Taher AT, Wali Y, Cruz MC, Charoenkwan P, Aydinok Y, Werner O, Govindaraju S, Romen F, Viprakasit V.
    Haematologica; 2024 May 01; 109(5):1413-1425. PubMed ID: 37855069
    [Abstract] [Full Text] [Related]

  • 14. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
    Tahir A, Hussain SI, Khan HS, Khalil S, Haider SZ, Lodhi MA.
    J Ayub Med Coll Abbottabad; 2021 May 01; 33(2):207-212. PubMed ID: 34137530
    [Abstract] [Full Text] [Related]

  • 15. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
    Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C.
    Eur J Haematol; 2008 Feb 01; 80(2):168-76. PubMed ID: 18028431
    [Abstract] [Full Text] [Related]

  • 16. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A.
    Eur J Haematol; 2017 Mar 01; 98(3):280-288. PubMed ID: 27859648
    [Abstract] [Full Text] [Related]

  • 17. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD.
    Blood; 2012 Aug 02; 120(5):970-7. PubMed ID: 22589472
    [Abstract] [Full Text] [Related]

  • 18. Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial.
    Rafati M, Karami H, Lashtoo-Aghaee B, Lashtoo-Aghaee B, Dabirian M, Avan R.
    Caspian J Intern Med; 2022 Aug 02; 13(1):61-69. PubMed ID: 35178209
    [Abstract] [Full Text] [Related]

  • 19. Transitioning Patients With Iron Overload From Exjade to Jadenu.
    Tinsley SM, Hoehner-Cooper CM.
    J Infus Nurs; 2018 Aug 02; 41(3):171-175. PubMed ID: 29659464
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR, Delhikumar CG, Ram Kumar G.
    Indian J Pediatr; 2021 Apr 02; 88(4):330-335. PubMed ID: 32661609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.